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This randomised, double-blind, placebo-controlled study was designed to evaluate the ability of the orally administered matrix
metalloproteinase inhibitor, marimastat, to prolong survival in patients with non-resectable gastric and gastro-oesophageal
adenocarcinoma. Three hundred and sixty-nine patients with histological proof of adenocarcinoma, who had received no
more than a single regimen of 5-ﬂuorouracil-based chemotherapy, were randomised to receive either marimastat (10 mg b.d.)
or placebo. Patients were treated for as long as was tolerable. The primary endpoint was overall survival with secondary
endpoints of time to disease progression and quality of life. At the point of protocol-deﬁned study completion (85% mortality
in the placebo arm) there was a modest difference in survival in the intention-to-treat population in favour of marimastat
(P=0.07 log-rank test, hazard ratio=1.23 (95% conﬁdence interval 0.98–1.55)). This survival beneﬁt was maintained over a
further 2 years of follow-up (P=0.024, hazard ratio=1.27 (1.03–1.57)). The median survival was 138 days for placebo and 160
days for marimastat, with 2-year survival of 3% and 9% respectively. A signiﬁcant survival beneﬁt was identiﬁed at study
completion in the pre-deﬁned sub-group of 123 patients who had received prior chemotherapy (P=0.045, hazard ratio=1.53
(1.00–2.34)). This beneﬁt increased with 2 years additional follow-up (P=0.006, hazard ratio=1.68 (1.16–2.44)), with 2-year
survival of 5% and 18% respectively. Progression-free survival was also signiﬁcantly longer for patients receiving marimastat
compared to placebo (P=0.009, hazard ratio=1.32 (1.07–1.63)). Marimastat treatment was associated with the development
of musculoskeletal pain and inﬂammation. Events of anaemia, abdominal pain, jaundice and weight loss were more common in
the placebo arm. This is one of the ﬁrst demonstrations of a therapeutic beneﬁt for a matrix metalloproteinase inhibitor in
cancer patients. The greatest beneﬁt was observed in patients who had previously received chemotherapy. A further
randomised study of marimastat in these patients is warranted.
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Gastric cancer is the fourth most common cause of cancer death in
Europe, with an incidence of 24 per 10
5 population in males and
16 per 10
5 population in females (Stadtlander and Waterbor,
1999). Even in the US, where there has been a sharp decline in
the incidence of gastric cancer over the past 50 years, the incidence
of adenocarcinoma of the gastro-esophageal junction has risen
rapidly (Devesa et al, 1998).
Gastric cancer spreads by local extension to form lymphatic,
peritoneal and distant metastases. As a result of early spread only
10–20% of patients present with resectable disease. For the
remainder, surgical debulking will be attempted in some, while
others will be considered inoperable. Until recently there has
been relatively little evidence of a survival beneﬁt for established
cancer therapies in this disease. However, results from a recent
US study have shown a signiﬁcant survival beneﬁt for the use
of adjuvant 5-ﬂuorouracil (5-FU) and radiation in patients
following curative resection (MacDonald et al, 2001) and a
meta-analysis of the available randomised evidence also supports
the use of adjuvant chemotherapy following curative resection
(Mari et al, 2000).
In patients with inoperable gastric cancer, the data regarding the
use of chemotherapy are less clear. A survival beneﬁt has been
shown for one regimen vs another (Cirera et al, 1999; Roth et al,
1999; Waters et al, 1999; Chao et al, 2000) and in a small number
of studies with small numbers of patients comparing chemotherapy
with best supportive care (Murad et al, 1993; Pyrhonen et al, 1995;
Glimelius et al, 1997). The absence of a large randomised study of
chemotherapy vs best supportive care has allowed the debate on its
merits to continue. As a result a wide range of 5-FU based
chemotherapy regimens are offered to patients, and a proportion
of patients are offered no cytotoxic therapy at all.
Recent changes in attitude towards the non-operative manage-
ment of solid gastrointestinal tumours have led to a renewed
interest in the development of novel agents. The rapid increase
in knowledge of the molecular and cellular biology of malignancy
over the last decade has enabled scientists to accurately target cellu-
lar pathways with synthetic compounds and inhibit these pathways
for potential therapeutic beneﬁt. Several of these strategies have
been tested in clinical trials in patients with a variety of tumour
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matrix metalloproteinases (MMPs).
The MMPs are a family of proteolytic enzymes that are respon-
sible for the breakdown of connective tissue proteins. These
enzymes play an important role in normal processes of growth,
differentiation and repair. The activity of MMPs is tightly regulated
at several levels including gene expression and inhibition by tissue
inhibitors known as TIMPs. There is now considerable evidence
however, that aberrant MMP expression contributes to the invasive
growth and spread of a variety of solid malignancies (Chambers
and Matrisian, 1997). MMP-2 (gelatinase A), MMP-9 (gelatinase
B) (Sier et al, 1996), MMP-7 (matrilysin) (Honda et al, 1996)
and MMP-14 (MT1-MMP) (Nomura et al, 1995) are over-
expressed in human gastric cancer. It is therefore feasible that
speciﬁc MMP inhibitors might restore the normal balance of
proteolytic activity and thereby prevent further tumour growth
and metastasis.
Marimastat (BB-2516) is a broad spectrum, low molecular
weight MMP inhibitor with IC50s against puriﬁed enzymes in the
low nanomolar range (Whittaker et al, 1999). The closely related
inhibitor batimastat (BB-94) has been shown to inhibit tumour
growth and spread in a range of cancer models (Chirivi et al,
1994; Eccles et al, 1996) and marimastat has been shown to inhibit
tumour growth in a xenograft model of human gastric cancer
(Watson et al, 1999). MMP inhibitors have not been shown to
cause tumour regression in cancer model studies and it was there-
fore proposed that these agents be tested in the clinic as oncostatic
treatments.
Support for the current study came from the results of a phase I
trial of marimastat in patients with advanced gastric cancer (Tier-
ney et al, 1999). Patients in this pilot study received marimastat at
doses of marimastat 25 mg o.d. or 50 mg b.d. An increase in
endoscopically observed ﬁbrous stroma, and a decrease in haemor-
rhagic appearance, were observed in approximately one third of
patients. These changes were frequently accompanied by signs of
improved clinical well-being. The dose of marimastat used in the
current study (10 mg b.d.) was selected on the basis of series of
phase II cancer antigen studies, which explored the biological activ-
ity and tolerability of the compound (Nemunaitis et al, 1998;
Primrose et al, 1999). The principal treatment-related side effect
recorded in these studies was musculoskeletal pain and inﬂamma-
tion, commonly in the shoulder girdle and joints of the hands.
These side effects usually resolved rapidly on treatment interrup-
tion, however it was judged that the more rapid onset of
musculoskeletal pain at doses above 10 mg b.d. would prohibit
chronic administration.
The current multi-centre randomised study was designed to
establish whether the encouraging biological activity seen in the
phase I study would translate into a signiﬁcant survival advantage
for gastric cancer patients receiving marimastat.
PATIENTS AND METHODS
Patient population
Patients with histologically or cytologically proven adenocarcinoma
of the stomach, which was locally advanced or metastatic, and was
considered inoperable, were eligible for inclusion. Adenocarcinoma
of the gastro-oesophageal junction was permitted if in the opinion
of the investigator the tumour was primarily gastric in origin. If a
non-curative surgical resection had been performed, patients were
required to have conﬁrmation of residual disease and to have
entered the study within 4 weeks of surgery. Previous ﬁrst-line 5-
ﬂuorouracil-based chemotherapy was allowed. Patients who
received chemotherapy must have entered the study between 2
and 6 weeks following the last dose, and must not have shown clin-
ical evidence of disease progression before entry. Patients
undergoing open surgery within 2 weeks or laparoscopic surgery
within 1 week of study entry; pregnant or lactating patients were
also excluded.
Patients were required to be aged over 18 years and have an
ECOG performance status of 0 or 1. Patients had to have adequate
bone marrow reserve at study entry, (absolute granulocyte count of
40.5610
9/L and platelet count of 450610
9/L). Adequate base-
line hepatic function (bilirubin5twice the upper limit of normal
and aspartate transaminase (AST), alanine transaminase (ALT)
51.5 times the upper limit of normal) and adequate renal function
(serum creatinine 51.5 times the upper limit of normal) were also
required. Patients were excluded if they had received radiotherapy,
more than one course of systemic anti-cancer therapy, any previous
investigational agent, hormonal anti-neoplastic therapy, or prior
exposure to a metalloproteinase inhibitor.
Signed and witnessed informed consent was obtained from each
patient prior to study entry. The study was performed in accor-
dance with the Declaration of Helsinki, approved by Institutional
Review Boards and local regulatory authorities and conducted in
accordance with the FDA Guideline on Good Clinical Practice.
Patient assignment
Patients were assigned to marimastat (10 mg b.d.) or matched
placebo in a ratio of 1:1 by means of a minimisation program
using the following criteria: centre, gender, prior chemotherapy
(yes/no), chemotherapy regimen, response to chemotherapy,
performance status, extent of disease at baseline (local/metastatic),
and prior non-curative surgery (yes/no). The minimisation
program also contained a random element in the event of tied
minimisation scores for assigning treatments (Taves, 1974).
Treatment
Marimastat or matched placebo were administered in a double
blind fashion as 10 mg capsules. If musculoskeletal toxicities devel-
oped, treatment was omitted until the symptoms had abated.
Patients could then restart treatment at the same dose. If patients
experienced a recurrence of their symptoms, treatment was again
omitted until the symptoms had abated and treatment could then
be restarted once daily (i.e. a 50% dose reduction). If the symp-
toms recurred again further treatment was at the physician’s
discretion, after consideration of the risk/beneﬁt ratio for the indi-
vidual patient. Once a dose reduction had been mandated, no
escalation to the previous level was permitted. Patients on treat-
ment were seen at 6 weeks, and then every 3 months, or at early
termination for any reason. Treatment assignments were kept in
sealed envelopes at British Biotech. The blind was only broken once
all data had been veriﬁed, collected and quality assured, and the
statistical analysis plan had been ﬁnalised and signed.
Endpoints and statistical analyses
The primary study endpoint was overall survival in the intention-
to-treat population. A secondary analysis of overall survival in the
sub-group of patients who had received chemotherapy was also
pre-deﬁned in the statistical analytical plan, since this sub-group
might differ in response or outcome from the chemonaive patients.
Progression-free survival, quality of life and safety and tolerability
were deﬁned as secondary endpoints. The original sample size for
this study was 150 per arm. This was increased to 180 per arm
when it became apparent that a higher than expected proportion
of patients were leaving the study due to early disease progression
(within 8 weeks of entry). The revised sample size was estimated to
be sufﬁcient to show a statistically signiﬁcant difference in survival
between the marimastat and placebo groups, assuming population
mortality rates at 18 months of 85% for placebo and 72% for mari-
mastat (a 15% relative reduction vs placebo), with at least 90%
power and using a=0.05 (two-tailed log rank test). The prospec-
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group had died or 18 months after the last patient was recruited,
whichever occurred sooner. This point was reached in January
1999 with 85% mortality in the placebo arm. A further 2-years
of survival follow-up have also been obtained up to January, 2001.
The treatment groups were compared using Kaplan-Meier survi-
val curves and tested using the log-rank test. In all survival
analyses, patients who were lost to follow up were censored at last
known date alive. In addition, these results were supplemented
with hazard ratios (HR) with a 95% conﬁdence interval using a
Cox proportional hazard model containing only treatment. Quality
of life data were analysed using a Wilcoxon rank-sum test and
proportions were analysed using a w
2 test.
Efﬁcacy and safety evaluation
The primary efﬁcacy endpoint in this study was survival. Treat-
ment continued until death, disease progression or drug toxicity
that warranted removal from the study. Patients could receive
salvage chemotherapy or other conventional anti-cancer therapy
once they had withdrawn from the study.
Time to disease progression was deﬁned as the time from mini-
misation to documented disease progression (clinical or
radiological). Progressive disease was deﬁned as a 425% increase
in the sum of the products of the largest perpendicular diameters
of all measurable lesions from the study nadir. If lesions were
not bi-dimensional then an unequivocal worsening of any evaluable
lesion as determined by more than one investigator, the appearance
of new lesions or death would constitute progressive disease. CT
scans were performed at baseline and thereafter at 3 monthly inter-
vals or at early termination if there was clinical suspicion of
relapse. Patients dying prior to documented progressive disease
were considered to have experienced progressive disease at death.
Quality of life was measured by the QLQ-C30 questionnaire at
screening, weeks 6 and 12 and every 3 months thereafter up to
36 months.
Medical history was recorded at baseline. Performance status,
full blood count and serum chemistry proﬁle were recorded at
baseline, after 6 weeks, 3 months and 3 monthly thereafter up to
18 months. All signs, symptoms and laboratory abnormalities were
assessed using the NCI CTC criteria for toxicities. In addition, a
speciﬁc rating for grading musculoskeletal toxicity was developed
for this study. Grade 1 for musculoskeletal toxicity was deﬁned
as aches and pains with no restriction of activity. Grade 2 was
deﬁned as having pain causing restriction of activity. Grade 3
was deﬁned as having pain and the presence of nodules or clinically
inﬂamed joints or tendons. Grade 4 was deﬁned as pain and the
presence of a contracture.
RESULTS
Patient characteristics
A total of 369 patients were recruited from 37 European hospitals
between October 1996 and October 1998. Of these, 185 received
marimastat and 184 received placebo. One patient in the marima-
stat arm was lost to follow-up. The baseline patient demographics
are shown in Table 1 and the pre- and post-study study treatments
are summarised in Table 2. The two treatment arms were well
balanced for known prognostic variables. The majority of patients
entered the study with advanced metastatic disease (80% stage IV,
73% M1). Overall, 25% of patients had undergone a partial
gastrectomy or oesophagogastrectomy and one third of the patients
had received chemotherapy prior to entering the study. A small
proportion of patients were offered salvage chemotherapy after
completing the marimastat study.
Seventeen patients were deemed to be protocol deviators, 10 in
the marimastat group and seven in the placebo group. Two mari-
mastat patients and one placebo patient had potentially curative
resections and entered the study without histological or radiologi-
cal conﬁrmation of residual or relapsed disease. Two marimastat
patients and one placebo patient had received prior radiotherapy.
Previous malignant disease was recorded for one marimastat
patient (testicular cancer) and two placebo patients (testicular
and cervical cancer). Six marimastat patients and three placebo
patients showed signs of disease progression between completion
of ﬁrst-line treatment and study entry, and did not take any study
drug even though they were minimised. In addition, six marimastat
patients and three placebo patients entered the study with disease
that would normally be considered resectable (T1-2, N0-1).
However, a combination of advanced age and overall frail condi-
tion precluded the possibility of resection. Although technically
these patients did not deviate from the protocol they may be
considered to have introduced an imbalance in the arms and this
is explored in the following section.
Pharmacokinetic analysis revealed mean plasma concentrations
of marimastat of 67.6 ng ml
71 at week 6 (n=147) and
49.2 ng ml
71 at week 12 (n=101). Due to variability in sampling
times these values cannot be regarded as true troughs. The concen-
trations were in line with expectations from previous studies and
equate to free-drug concentrations of approximately 3–4 times
the IC50 for the target enzymes such as gelatinase A and MT1-
MMP.
Efﬁcacy analyses
The primary analysis was performed when 85% of patients in the
placebo arm had died. The primary endpoint of the study was
met when the nine patients who did not take the study drug were
excluded (modiﬁed ITT) (P=0.043 log-rank test, HR=1.27 (1.00–
1.60)), but failed to meet the endpoint when all patients are
included (ITT) (P=0.07 log-rank test, HR=1.23 (0.98–1.55)). The
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Table 1 Patient demography at baseline
Placebo Marimastat
Number of patients 184 185
Male/Female (%) 71/29 71/29
Age (median, years) 68 68
Gastric adenocarcinoma (%) 100 100
Days from diagnosis (median) 71 69
ECOG (0/1) 56/128 66/119
Tumour stage* (I/II/III/IV) 0/5/30/149 2/6/32/145
Metastases (M1) 132 136
Albumin (median, g l
71)3 83 8
LDH (median, iu l
71) 169 169
*AJCC 1988 classiﬁcation.
Table 2 Pre- and post-study treatment
Placebo Marimastat
Number of patients 184 185
Prior surgical debulking 46 46
Prior chemotherapy 62 61
epirubicin, cisplatin, 5-FU 31 30
other 5-FU combination 26 29
single agent 5-FU 5 2
CR/PR/SD/NA* 5/31/25/1 5/31/25/0
Post-study chemotherapy 23 16
Post-study radiotherapy 4 7
Post-study surgery 0 2
*Complete or partial response, stable disease, not assessable relative to prior
chemotherapy.
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further 2 years of follow-up (ITT, P=0.024 log-rank test, HR=1.27
(1.03–1.57)), with median survival times of 160 days for marima-
stat and 138 days for placebo, and 2-year survival of 9% and 3%
respectively (Figure 1). The modiﬁed ITT analysis showed a
marginally greater survival beneﬁt (P=0.014 log rank test,
HR=1.30 (1.05–1.61) for result after 2 years of additional
follow-up.
Analysis of overall survival in the predeﬁned sub-group of
patients who had received prior chemotherapy revealed a signiﬁ-
cant beneﬁt for marimastat at the primary analysis point
(P=0.045 log-rank test, HR=1.53 (1.00–2.34)). This survival differ-
ence increased with 2 years of additional follow-up (P=0.006 log-
rank test, HR=1.68 (1.16–2.44)), with median survival times of
253 days for marimastat and 175 days for placebo, and 2-year
survival of 18% and 5% respectively (Figure 2). Importantly, there
was no evidence of an adverse effect on survival in the patients
who had not received chemotherapy (P=0.515 log-rank test,
HR=1.09 (0.84–1.40)).
There was also a signiﬁcant beneﬁt in progression-free survival
at the primary analysis point (P=0.014 log-rank test, HR=1.31
(1.05–1.63)). This difference was maintained over the 2 years of
additional follow-up (P=0.009 log-rank test, HR=1.32 (1.07–
1.63)) (Figure 3).
The possibility of bias or imbalance between the arms was
explored as an explanation for the survival differences. Interactions
between several factors precluded a single multifactorial analysis to
adjust for baseline prognostic factors. There was a small imbalance
in ECOG status in the ITT population with 70% of placebo
patients having a status of 1 vs 64% of marimastat patients. Other
baseline prognostic factors were well balanced for the ITT popula-
tion. The chemotherapy sub-group was found to have minor
imbalances in favour of marimastat for ECOG status (ECOG 1
57% vs 63% for marimastat and placebo respectively), and in
favour of placebo for metastases (M1 72% vs 68%) and no prior
resection (74% vs 65%). Another source of imbalance was recruit-
ment of three placebo patients and six marimastat patients who
had resectable disease (T1-2, N0-1). The chemotherapy sub-group
contained one patient with resectable disease in each arm. When
these patients were excluded, the overall survival beneﬁt after 2
years additional follow-up was reduced and only just signiﬁcant
(P=0.049 log-rank test, HR=1.24 (1.00–1.53)). However, the result
for the chemotherapy sub-group was largely unchanged (P=0.010
log rank test, HR=1.63 (1.12–2.37)).
The robustness of the survival beneﬁt in the chemotherapy sub-
group was explored further by Cox regression analyses to account
for individual prognostic factor imbalance. None of the factors
diminished the hazard ratio below 1.61, and the imbalance in prior
surgical debulking increased the hazard ratio to 1.77. Furthermore,
when divided in two halves on the basis of recruitment period, a
survival trend in favour of marimastat is seen in both halves
(HR=1.51 and HR=2.04).
Quality of life analyses using the EORTC-QLQC30 instrument
were performed at baseline, 6 weeks, 12 weeks and at 3-monthly
intervals thereafter. There was no statistically signiﬁcant difference
between placebo and marimastat in standardised area under the
curve (AUC) (mean 57.9 vs 56.5, P=0.49) or change from baseline
standardised AUC (mean 70.87 vs 73.82, P=0.18) over the ﬁrst
12 weeks of the study (Wilcoxon rank-sum tests). Further analysis
was prevented by a marked reduction in the number of patients
remaining on study and able to complete the questionnaire.
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Marimastat (n=185) median = 160 days
Placebo (n=184)      median = 138 days
Hazard ratio = 1.27 (1.03 – 1.57)
P=0.024
Figure 1 Overall survival (intention to treat).
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Figure 2 Overall survival (Chemotherapy sub-group).
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Hazard ratio = 1.32 (1.07 – 1.63)
P=0.009
Figure 3 Progression-free survival (intention to treat).
Table 3 NCI-CTC graded adverse events (all causalities)
Placebo Marimastat
Adverse event (%) Grade 1/2 Grade 3/4 Grade 1/2 Grade 3/4
Vomiting 32.6 5.5 30.7 5.0
Constipation 30.9 5.5 27.9 7.3
Nausea 30.4 4.4 28.5 5.0
Musculoskeletal pain 22.7 0.6 43.6 12.8
Neuro: cortical 22.7 10.5 33.5 12.3
Weight gain/loss 22.7 2.8 15.6 1.1
Infection 17.1 3.9 17.3 6.1
Diarrhoea 15.5 1.1 14.5 2.2
Neuro: motor 15.5 7.1 11.2 7.8
Haemorrhage 9.9 3.9 10.1 3.4
Skin 9.4 2.8 13.4 1.1
Neuro: sensory 9.4 0.6 8.4 0
Pulmonary 8.8 9.9 11.7 7.3
Fever 6.6 0 4.4 1.7
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Treatment related adverse events for marimastat appeared to be
conﬁned to the expected side effects of musculoskeletal pain
and inﬂammation. In total 18 marimastat patients (10%) and
two placebo patients (1%) withdrew from the study due to
adverse events. Events of arthralgia, joint stiffness, limb pain,
general pain, myalgia, peripheral oedema, dysphagia and fatigue
were more common in the marimastat treatment arm (45%
absolute difference). The majority of these events were related
to the musculoskeletal syndrome that has been described for
marimastat and several other MMPIs. The condition is charac-
terised by musculoskeletal pain and inﬂammation, most
commonly originating in the upper shoulder girdle or hands.
The condition tended to develop in the second and third months
of treatment at 10 mg b.d. and in ﬁve cases led to contractures
of the palm and ﬁngers. A peripheral oedema of the hands was
also sometimes seen in patients with these musculoskeletal side
effects. The condition was managed by treatment interruption
and many patients were able to resume treatment on the same
or lower dose after a break of 2–3 weeks. Severe events could
generally be avoided by early treatment interruption. A more
general tiredness, recorded in a higher incidence of both fatigue
and somnolence, may also be associated with marimastat treat-
ment.
Events of abdominal pain, jaundice, weight loss, anaemia, and
ascites were more common in the placebo treatment arm (45%
absolute difference). The increased incidence of anaemia was also
evident in a 32% increase in transfusion requirement for the
placebo arm over marimastat. This is consistent with the reduction
in tumour haemorrhage observed endoscopically in the phase II
study of marimastat in advanced gastric cancer, and with the
intended therapeutic effect of marimastat.
The NCI-CTC graded adverse events (all causalities) are shown
for both arms in Table 3. Grades 3 and 4 musculoskeletal events
were recorded in 12.8% of patients compared to 0.6% of placebo
patients (P=0.001, w
2 test). A comparison of NCI-CTC graded
laboratory abnormalities revealed an increased incidence of grade
3/4 low hemoglobin (57.9 g dl
71) in the placebo arm (10.5% vs
2.8%, P=0.003, w
2 test) (Table 4). This was consistent with a higher
transfusion requirement in placebo patients.
The signiﬁcance of the musculoskeletal side effects of marimastat
can be seen in Figure 4. This graph shows the proportion of
patients taking the prescribed dose of 10 mg b.d. marimastat or
placebo without interruption over time, expressed as a percentage
of patients alive. After 3 months only 43% of marimastat patients
are still taking study treatment twice daily and this falls to 11% by
6 months. The corresponding values for the placebo arm were 73
and 50%. The decline in compliance in the placebo arm reﬂects
both the background incidence of musculoskeletal conditions in
cancer patients and also the deterioration in the patients’ condi-
tion.
DISCUSSION
The primary result of this randomised trial shows a modest survi-
val beneﬁt for marimastat treatment in the overall population of
gastric cancer patients. The more interesting result, however, is
seen in the sub-group of patients who had received prior
chemotherapy. The survival beneﬁt in this group, if true, is clini-
cally signiﬁcant with an absolute 2-year survival difference of
13%, and a 45% improvement in median survival. There are
obvious concerns regarding the interpretation of a result from a
sub-group even if, as in this case, it was pre-deﬁned. For this
reason the robustness of the result was explored further. Cox
regression analysis indicated that imbalances of individual prognos-
tic factors were unlikely to account for the survival difference. A
survival beneﬁt in favour of marimastat was also observed in both
halves of the chemotherapy sub-group when divided arbitrarily on
the basis of recruitment period. Finally, the result is not signiﬁ-
cantly reduced by the exclusion of the single patient in each arm
of the sub-group who entered the study with potentially resectable
disease (T1-2, N0-1).
It is important to note that the chemotherapy sub-group is a
selected population, including as it does only those patients who
had responded to chemotherapy or who had shown stable disease
during treatment. The reason these patients responded to marima-
stat may be related to the fact that they responded in some way to
the chemotherapy. Alternatively, the marimastat beneﬁt may be
related to the fact that this sub-group excludes those patients with
more advanced or more rapidly progressive disease.
The safety and tolerability of marimastat was generally good,
with only those events related to the musculoskeletal syndrome
being signiﬁcantly elevated above placebo. The musculoskeletal side
effects clearly limit the duration of treatment for the majority of
patients. However, the condition can be readily monitored and
can be managed by treatment interruptions. In this study 21
placebo patients and 69 marimastat patients interrupted treatment,
with a median duration of 14 days for both groups. Experience in
this and other studies has shown that severe musculoskeletal side
effects can usually be avoided by prompt treatment breaks. It is
possible that improved treatment schedules and pre-medications
could be employed to allow longer term dosing.
Early expectations for the use of MMP inhibitors in cancer treat-
ment were high, but previous clinical trials with this new class of
agent have been disappointing. Marimastat at a dose of 25 mg
b.d. showed comparable 1-year survival to gemcitabine in patients
with non-metastatic pancreatic cancer (Bramhall et al, 2001). A
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Figure 4 Patients taking original twice-daily dose as a percentage of
those alive.
Table 4 NCI-CTC graded laboratory abnormalities (all causalities)
Laboratory
Placebo Marimastat
parameter (%) Grade 1/2 Grade 3/4 Grade 1/2 Grade 3/4
Alkaline phosphatase 27.6 5.5 21.8 3.9
Hyperglycemia 27.6 2.2 35.2 1.1
Haemoglobin 22.7 10.5 23.5 2.8
Transaminases 10.5 2.8 11.7 1.1
Bilirubin 4.4 4.4 3.9 6.1
Creatinine 2.2 0 2.8 0
White blood count 1.1 0 2.2 0
Platelets 1.1 0 3.9 0.6
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gemcitabine, however, failed to show any evidence of survival bene-
ﬁt compared to gemcitabine alone. Studies of marimastat in
patients with glioblastoma (British Biotech, 2000a), ovarian cancer
(British Biotech, 2000b) and small cell lung cancer (British Biotech,
2001) also failed to show evidence of clinical beneﬁt. Randomised,
placebo-controlled studies with the MMP inhibitor AG3340 in
patients with non-small cell lung cancer and prostatic cancer were
stopped early on grounds of lack of efﬁcacy (Agouron, 2000). Of
more concern was the early termination of a randomised place-
bo-controlled study of the MMP inhibitor BAY12-9566 in
patients with small cell lung cancer. Patients receiving BAY12-
9566 showed a signiﬁcantly poorer survival than placebo patients
(Hughes, 1999). Reassuringly, an adverse effect on survival was
not observed in the marimastat small cell lung cancer study (Brit-
ish Biotech, 2000c).
Against this background the current results are encouraging.
This study of marimastat in patients with gastric cancer provides
the ﬁrst indication of a survival beneﬁt for an MMP inhibitor.
The reason that beneﬁt is seen with this cancer and not others
may be due to inadequate tissue concentrations of the drug.
Biodistribution studies with
14C-marimastat in the rat have shown
very high concentrations of marimastat in the stomach wall even
after washing. By contrast the levels in lung were low (British
Biotech – unpublished data).
In conclusion, these results support a possible role for marima-
stat as a maintenance treatment following a response or stable
disease to chemotherapy. 5-FU based combination chemotherapy
is gaining acceptance as the standard of care for gastric and
gastro-oesophageal cancer patients with reasonable performance
status, both in Europe and North America. In this setting, MMP
inhibitor therapy may prove to be a valuable component of the
anticancer armoury, and conﬁrmatory trials of this novel agent
are warranted.
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